Using the Surveillance, Epidemiology and End Results (SEER)-Medicare database, Hung-Jui Tan, MD, of the University of Michigan in Ann Arbor, and colleagues identified 1,925 patients treated with PN and 5,213 treated with RN for T1a kidney cancer from 1992 to 2007.
With a median follow-up of 58 months, patients treated with PN had a significant 46% decreased risk of death compared with those treated with RN. The results corresponded with predicted survival advantage rates of 6%, 12%, and 16% at two, five, and eight years post-treatment, respectively.
The researchers noted that the survival benefit associated with PN was most pronounced for younger patients and those with comorbid medical conditions.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.